Current Approaches for New TB Drugs

Author(s): Shilpika Pandey, Isha Soni, Neha Topno, Arunava Dasgupta, Sidharth Chopra

Journal Name: Current Respiratory Medicine Reviews

Volume 10 , Issue 2 , 2014

Become EABM
Become Reviewer

Graphical Abstract:


Tuberculosis is essentially a curable disease but inspite of a WHO approved DOTS therapy, it still continues to ravage mankind. This situation is exacerbated by long course of chemotherapy, increasing drug resistance and co-emergence with HIV. The TB drug pipeline remained stagnant for a long time with no new drug approved till FDA approval for Bedaquiline. This situation has now improved with a number of agents in pre-clinical and clinical development against M. tuberculosis. In this review, we are focusing on some of the newer drugs in discovery and preclinical development against M. tuberculosis.

Keywords: Clinical strains, drugs, MIC, Mycobacterium, pre-clinical development, tuberculosis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [88 - 96]
Pages: 9
DOI: 10.2174/1573398X10666140813201210
Price: $65

Article Metrics

PDF: 19